PSMA-PET Imaging in the Biochemical Recurrence Setting

The goal of the trial is to improve quality of life by identifying patients who can safely reduce or avoid treatment with hormone therapy.

In this podcast episode, Adam B. Murphy, MD, MBA, MSCI, discusses the need to increase diversity in clinical trials, specifically focusing on studies in prostate cancer.

The safety review committee recommended that the phase 2 portion proceed with the 8 GBq dose.

Zeyad Schwen, MD, a urologic oncologist at Cleveland Clinic, discusses how patient factors and cancer characteristics are key to deciding between focal therapies and whole gland treatment for prostate cancer.

A recap of the FDA submissions and regulatory decisions in urology from February 2025.

Data from the VAPOR 2 trial are intended to support a submission to the FDA for 510(k) clearance of the device.